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Malignant melanoma of the uvea is remarkable for purely haematogenous dissemination and its tendency to metastasise to the
liver. Although the liver is involved in up to 95% of patients, 50% of these also develop extrahepatic metastases, most often in
the lungs, bone, skin, and brain. The only effective treatments reported to date relied on hepatic arterial chemoembolisation
or -perfusion. The objective of this study was to establish a therapy protocol addressing patients with both sole liver
involvement and systemic disease. Forty-eight patients with metastatic ocular melanoma received fotemustine 100 mg m
72
either as 60-min infusion into the hepatic artery or as 15-min infusion via a peripheral vein, depending on the metastatic sites
involved, i.e., restriction to the liver or hepatic together with extrahepatic disease. For the ﬁrst treatment cycle this infusion
was repeated after one week. For all cycles, subsequent to a three week resting period, patients received an immunotherapy
consisting of subcutaneous interleukin 2 and interferon a2. Although objective responses were more frequent within the
cohort receiving intraarterial fotemustine (21.7 vs 8%), this difference did not translate into a signiﬁcant beneﬁt in overall
survival, i.e., 369 and 349 days, respectively. Of note, this overall survival is much longer than that repeatedly reported for
stage IV uveal melanoma not treated with fotemustine, suggesting a therapeutic activity of this cytostatic drug even after
systemic administration.
British Journal of Cancer (2002) 87, 840–845. doi:10.1038/sj.bjc.6600521 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: ocular melanoma; hepatic metastases; extrahepatic metastases; immune therapy; chemotherapy
The annual incidence of uveal melanoma, the second most
common type of primary malignant melanoma in humans, is in
the range of 0.47 to 0.79 new cases per 100000 individuals (Shields
et al, 1996; Chang et al, 1998; Woll et al, 1999). Improvement of
the treatment of primary uveal melanoma over the past years,
enabling the preservation of the eye and its remaining visual func-
tion, did not, unfortunately, reduce the rate of subsequent tumour
dissemination (Shields et al, 1996; Seregard, 1996). The 5-year
survival rate is approximated between 65 and 81% but decreases
to 50% for large tumours (Shields et al, 1996).
Uveal melanoma is remarkable for purely haematogenous disse-
mination and its tendency to metastasise into the liver (Eskelin et
al, 1999; Gragoudas et al, 1991). Hepatic metastases are initially
present in 40–60% of patients and, eventually, the liver is involved
in up to 95% of patients. Nevertheless, 50% of patients develop
extrahepatic metastases, most often in the lungs, bone, skin, and
brain. Delayed dissemination is rather frequent; its occurrence,
however, restricts life expectancy to less than 5 months (Gragoudas
et al, 1991).
Metastases are detected by screening examinations or inciden-
tally, with one-third of patients being asymptomatic at the time
of diagnosis (Eskelin et al, 1999). While annual abdominal ultraso-
nography and chest X-rays are performed in most European
countries for early detection of disseminated disease, some autho-
rities question the value of screening, in the absence of any truly
effective therapy for metastatic disease. Indeed, until recently, there
had been no effective systemic treatment for metastatic uveal mela-
noma (Nathan et al, 1997). The largest series reported with
treatment by DTIC, usually in combination with other drugs and
bioactive agents, had a response rate of below 1% with no
improvement of survival noted (Bedikian et al, 1995; Woll et al,
1999).
Regional intraarterial chemotherapy increases the concentration
of the antineoplastic drug in hepatic metastases. For uveal melano-
ma, intrahepatic chemotherapy administration has the theoretical
beneﬁt of directly targeting the clinically most relevant site and
thereby concentrating the antineoplastic activity. To this end,
intraarterial chemoembolisation or perfusion has been reported
to induce both complete and partial responses in patients with
metastatic uveal melanoma. Bedikian reported a 36% objective
response rate induced by cisplatin-based chemoembolisation (Bedi-
kian et al, 1995). The group of Leyvraz treated 31 patients by the
intraarterial administration of fotemustine, a nitrosurea that is
characterised by a high hepatic extraction rate (Leyvraz et al,
1997). This treatment resulted in a response rate of 40% with four
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www.bjcancer.compatients in complete remission (13%). The median overall survival
was 14 months with seven patients surviving 42 years. Although
the fotemustine concentration in the liver was calculated to be at
least eight-fold higher than in normal tissue, the occurrence of
myelosuppression with grade III or IV neutropenia or thrombocy-
topenia was indicative of a systemic spillover. This spillover may
explain the low incidence of subsequent extrahepatic disease mani-
festations despite the long course of the disease, suggesting the
systemic activity of fotemustine. Data on systemic fotemustine in
uveal melanoma, however, are scarce (Terheyden et al, 1998,
2000). If indeed active, systemic fotemustine would be more conve-
nient to administer with the lack of side effects associated with
intraarterial hepatic catheters like thrombosis and infection. Its efﬁ-
cacy and toxicity needs thus to be deﬁned in a direct comparison
with intraarterial chemotherapy.
At ﬁrst sight, uveal melanoma seems to be a poor target for immu-
notherapeutic approaches. They arise in an immune-privileged site
that can sustain the growth of foreign tissues due to different
mechanisms for suppression of immune responses (Ijland et al,
1999; Ksander and Chen, 1999). Notably, lack of expression of
MHC class I on primary uveal melanoma was found to be correlated
with a better patient survival suggesting natural immunity to exert a
protective role in the development of metastatic disease (Blom et al,
1997a). Paradoxically, work with animal models for intraocular
tumours has demonstrated that adoptively transferred T cells can
in principle be effective against such tumours (Sutmuller et al,
2000). Moreover, metastases from human uveal melanoma express
both MHC class I as well as a variety of melanoma associated anti-
gens, and cell lines established from metastatic lesions are excellent
targets for lysis by tumour-speciﬁc CTL in vitro (Blom et al, 1997b;
Sutmuller et al, 2000). This is in accordance with the fact that several
– though still preliminary – clinical reports indicate a therapeutic
effect of different immune stimulatory approaches (Dorval et al,
1992; Terheyden et al, 2000; Woll et al, 1999; Nathan et al, 1997).
The aim of the present study was to evaluate the activity of a
combination of these promising treatment options in a prospective
phase II trial. To this end, chemotherapy with fotemustine followed
by immune modulation with interleukin 2 and interferon a was
given to treat patients with metastatic uveal melanoma. The appli-
cation route of fotemustine was stipulated according to the
presence of sole hepatic tumour manifestations or the occurrence
of extrahepatic metastasis.
PATIENTS AND METHODS
The protocol was in accordance with the Declaration of Helsinki
and was approved by the local ethic committees. All patients gave
informed consent prior to enrolment into the study.
Eligibility
Eligibility criteria included measurable sites of distant metastases of
uveal melanoma that were not amendable to surgery and did not
involve the CNS, evidence of tumour progression in two subse-
quent staging investigations, and no prior systemic therapy
within six weeks of the start of therapy. Each patient was evaluated
with a complete history, general physical examination, sonography
of the inguinal, axillary and cervical lymph nodes, as well as CT
scans of the head, neck, chest, and abdomen. Patients were enrolled
into the study and therapy was initiated within 2 weeks after this
initial work up. In addition, to be eligible, patients had to have
normal blood counts (absolute neutrophil count 41500 ml
71
and platelet count 4100000 ml
71), liver function (alanine amino-
transferase, aspartate aminotransferase, and alkaline phoshatase
levels less than two times normal and total bilirubin level
51.5 mg ml
71), and renal function (blood urea nitrogen and
creatinine levels less than two times normal), a Karnovsky perfor-
mance score of at least 80%, and a life expectancy of more than
three months. Patients with a history or symptoms of a signiﬁcant
cardiac disease were excluded.
Treatment protocol
A vignette of the treatment protocol is shown in Figure 1. Fotemus-
tine (Muphoran
1, Servier, France), which is distributed as a freeze-
dried sterile powder, was ﬁrst dissolved in 2 ml ethanol solvent per
100 mg and subsequently diluted in 100 ml 5% dextrose. All these
measures as well as the administration to the patient were performed
under strict light protection. Fotemustine was applied in a dose of
100 mg m
72 either via the hepatic artery over a period of 60 min
or via a peripheral vein as a 15-min infusion on day 1. Only for
induction, the fotemustine application was repeated on day 8. For
the intraarterial infusion, an angiography catheter was placed into
the hepatic artery by repeated puncture of the femoral artery. The
correct position was controlled by angiography preceding each
chemoperfusion. Prophylactic antiemetic treatment consisted of
intravenous 5-HT3 antagonists such as ondansetron.
The immune modulating therapy was started on day 31 and
consisted of subcutaneous injections of 10610
6 IU m
72 IL-2 bis
in die on three consecutive days. After a 2 day break, on days
36, 38 and 40 the patient received a subcutaneous dosage of
10610
6 IU m
72 interferon a2 and 5610
6 IU m
72 IL-2 (3 doses
in total). Although the immunotherapy schedule was designed as
an outpatient protocol, several patients were hospitalised due to
logistic reasons. The following treatment cycles were started with
the single dosage of fotemustine 3 days after the last cytokine
application (day 43). Vital signs, i.e. blood pressure, heart rate,
and temperature, were monitored three times per day. In addition,
patients input and output criteria were recorded. Fluid retention of
more than 5% of the body weight was treated with furosemide. IL-
2 was administered at 50% dose in cases of signiﬁcant hypotension
or when the creatinine level rose to three times of the normal level.
Patients showing evidence of tumour progression after two
cycles were regarded as non-responders. Patients with stable
diseases or regression after two cycles were offered additional treat-
ment cycles to achieve maximal antitumour activity.
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Fotemustine
100 mg m
–2
Il-2 10 ´ 106 IU m–2 bid
IL-2 5 ´ 106 IU m–2
IFN-a 10 ´ 106 IU m–2
1                8               15               22              29              36              43                50     days
Figure 1 Treatment schedule.
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The ﬁrst assessment of treatment activity was performed 3 months
after initiation of therapy, which was usually prior to the third
treatment cycle. Best responses were deﬁned as follows: Complete
responses (CRs) characterise the disappearance of all tumour mani-
festations, whereas partial responses (PRs) indicate decreases of
550% of the sum of the products of all diameters of all measur-
able lesions; the term objective response (OR) encompassed CR
and PR. Stable disease (SD) was deﬁned as a decrease of 450%
or an increase of 425% without the appearance of any new lesion.
Progressive disease (PD) comprised all stages not already deﬁned,
including the appearance of any new lesion. Time to progression,
i.e. progression free survival, was measured from the ﬁrst day of
treatment to the ﬁrst onset of tumour progression. Overall survival
was measured from the ﬁrst day of treatment to the last documen-
ted staging examination, i.e. the date last seen. The Kaplan–Meier
technique was used to calculate survival data. The log-rank test was
used to analyse survival differences among subgroups of patients.
All eligible patients were included in the survival analysis which
was performed in June 2001.
Bivariate analysis of the relationships between pre-treatment
factors and responses were assessed according to the w
2, the U-test
following Mann–Whitney or the student’s t-test, depending on the
nature and distribution of the data. A P-value of 50.05 was
considered to be signiﬁcant. The binominal conﬁdence intervals
are given in the range of 95%. All calculations were performed
using MEDAS statistical software (Grund EDV-Systeme, Margets-
ho ¨chheim, Germany).
RESULTS
Patients
All patients diagnosed with disseminated ocular melanoma
admitted for therapy between December 1996 and October 2000
were considered to be treated according to protocol. Forty-eight
patients were found to be eligible to be enrolled into the study.
Patients characteristics are listed in Table 1. Women accounted
for about 60% of all patients. The median time between the diag-
nosis of the primary tumour and the occurrence of metastases was
almost 3 years. Approximately 60% of the eyes had been surgically
removed while the others were subjected to brachytherapy. Liver
metastases were present in 45 of the patients and in 23 patients this
was the only site of metastases; only three patients did not show
any sign of liver involvement. If present, liver involvement was
generally found in form of multiple or diffuse metastases. Localisa-
tion of non-hepatic metastases included the lungs, skin, soft tissues,
and bones with decreasing frequency. The majority of the patients
were diagnosed with disseminated disease due to symptoms as at
that time no formalised follow-up schedule was inaugurated. The
median serum lactate dehydrogenase (LDH) level was 450 U l
71
for the cohort of patients suffering from liver metastases only
and 365 U l
71 for those with additional or sole systemic metas-
tases. The upper normal limit for LDH is 240 U l
71.
Toxicity
The most prominent side effect due to fotemustine was thrombo-
cytopenia which occurred in 16 patients but never exceeded grade
3 nor needed thrombocyte substitution (Table 2). A more promi-
nent systemic toxicity of intravenous applications was reﬂected by
the more common occurrence of leukocytopenia in the group of
intravenous application of fotemustine. Platelet counts of less
75.0610
9 l
71 were observed in 12 patients within the i.v. group
in contrast to four patients in the i.a. group (P=0.028). It arose
most frequently within the ﬁrst three weeks of the induction cycle.
Dose modiﬁcation of fotemustine due to myelosuppression was
only necessary in three patients. Nausea and vomiting was very rare
and readily amended by an increased dosage of 5-HT3 antagonists.
Alopecia was not observed.
In two patients receiving intraarterial fotemustine we observed
gastroenteric complications; one patient developed an erosive
gastritis, the other a gastric ulcer. These complications are likely
due to an atypical blood supply of the stomach via the hepatic
artery which was not obvious by angiography. Other complications
of the intraarterial catheter included one case of a dissection of the
artery wall and one of an angiospasm; both incidences prevented
additional courses of intraarterial chemoperfusion. The dissection
of the A. hepatica occurred after the fourth intraarterial application
of fotemustine in a patient achieving SD. No increase in serum
levels of liver enzymes nor alterations of liver function were
evident. The angiospasms of the hepatic arteria occurred after
two successful i.a. applications during the third attempt. Subse-
quent cycles were given i.v.
According to immunotherapy, we evaluated 79 treatment cycles
in 32 patients. Toxicity was evaluated after two cycles of therapy at
the time of the staging using toxicity forms; in patients receiving
more than four cycles the subsequent cycles were not documented
in such detail (22 cycles). The frequency of toxicities of World
Health Organisation (WHO) grade 3 or more are summarized in
Table 3. Side effects due to immune modulation with IL-2 and
interferon a2 were regularly present, but rarely severe in nature.
No patient was excluded from the study because of unmanageable
toxicities. Objective side effects remained stable or decreased with
the number of treatment cycles.
Therapeutic activity
Of the 48 patients, only one patient (2%) achieved a CR and six
(12.5%) a PR, for an overall response rate of 14.5% (95% conﬁ-
dence interval, 6.1 to 28.4%). Five of these objective responses
were observed in the cohort of patients receiving fotemustine
intraarterially, while only two (one CR and one PR) of 25 patients
in the i.v. therapy group experienced an OR. Figure 2 exemplary
depicts resolving liver metastases of the one patient experiencing
the CR. The duration of objective responses extended over a
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Table 1 Patients characteristics
i.a. (n=23) i.v. (n=25)
Gender
Male 9 11
Female 14 14
Age (years) median 60 (59–62) median 56 (53–58)
Localisation
Liver alone 23 –
Liver+other – 22
Lungs – 14
Lymph nodes – 10
Bones – 5
Skin, brain, etc. – 11
Type of liver involvement
Solitary – –
Multiple 17 17
Diffuse 6 6
None – 2
Time to distant
metastases (days)
median 1090 (823–1320) median 1080 (990–1215)
LDH (U l
71)
Pretherapeutic median 450 (266–493) median 365 (308–540)
above normal limits 16 18
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objective responses, we observed that for 18 (37.5%) patients
disease progression was stopped or at least slowed down to a
degree that they were classiﬁed as stable disease. Notably, these
patients experienced a median progression free survival of almost
one year, range 155 to 855 days resulting in an overall survival
similar to that observed after an OR, i.e. the median overall survi-
val of patients with an OR (581 days, range 346 to 826 days) was
not signiﬁcantly improved compared to those with a SD (448 days,
range 175 to 1020 days) (Figure 3). In contrast, the overall survival
of patients neither achieving an OR nor a SD was 321 days.
Prognostic parameters
Based on multivariate analysis only LDH level maintained its role
as a pretherapeutic parameter for survival (P=0.0058). Other para-
meters, such as performance status, interval between primary
tumour and metastatic disease, sex, age, hepatic function, prether-
apeutic serum concentration of S100, or number and localisation
of metastatic sites had no signiﬁcant impact on overall survival.
DISCUSSION
Despite encouraging new treatment options for disseminated uveal
melanoma an effective standard therapy is still missing (Woll et al,
1999; Shields, 1993); thus, systematic therapeutic trials are manda-
tory for the development of an effective treatment regimen. Recent
reports demonstrated the prospect of both regional and systemic
treatment options (Leyvraz et al, 1997; Nathan et al, 1997; Salmon
et al, 1998). However, to date no randomised trial was reported to
demonstrate the superiority of either therapeutic strategy. In this
respect, the present report is no exception; however, besides being
the largest prospective trial in disseminated uveal melanoma
reported to date, the obtained data allow to compare the clinical
efﬁcacy of the most active single chemotherapeutic drug depending
on the administration route, i.e. intraarterial versus intravenous.
Although the treatment arms were not randomised, but stratiﬁed
according to the presence or absence of extrahepatic metastases,
the presented data demonstrate the therapeutic activity of systemi-
cally applied fotemustine. It is important to note that the patient
group receiving intravenous fotemustine should have the worse
prognosis as in most patients the liver plus additional sites were
involved. Nevertheless, the overall survival for these two groups
was comparable with a median of 369 days (range 160 to 1020
days) and 349 days (range 52 to 1535 days), respectively. The high-
er response rate achieved for the patients in the intraarterial
treatment group reﬂects high response rates for other tumour types
(Leyvraz et al, 1997). The present study is conﬁrming a previous
report by Leyvraz et al (1997) on the therapeutic efﬁcacy of fote-
mustine for the treatment of hepatic metastases of uveal
melanoma. However, the incidence of OR induced by fotemustine
in that study was signiﬁcantly higher than the frequency of OR
observed by us, i.e. 40 vs 22%. Several reasons may explain the
advantageous response in the patients population reported by
Leyvraz: (1) the majority of patients were subjected to surgical
resection of liver metastases, (2) all patients were asymptomatic
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Table 2 Toxicity due to chemotherapy. Comparison of i.a. and i.v. fotemustine associated toxicity.
Worst grade for each patient is given
i.a. i.v.
51.0752.0610
9 l
71 51.0610
9 l
71 51.0752.0610
9 l
71 51.0610
9 l
71
Leukocytes 2 0 6 0
510.07575.0610
9 l
71 510.0610
9 l
71 510.07575.0610
9 l
71 510.0610
9 l
71
Thrombocytes 4 0 12 0
Table 3 Toxicity associated with immunotherapy. Seventy-nine out of
163 cycles were evaluated for side effects in 32 patients
0 I II III IV
Temperature 6 44 25 3 1
Chills 16 36 19 6 2
Fatigue 6 52 15 5 1
Appetite 29 33 13 1 3
Nausea 22 44 12 0 1
Diarrhoea 65 14 0 0 0
Skin 26 41 12 0 0
Mucous membranes 69 9 1 0 0
Hair loss 66 9 4 0 0
Lungs 64 12 2 1 0
ECG-changes 67 6 2 2 2
Hypotension 46 17 11 4 1
Allergy 73 5 1 0 0
Fluid retention 64 10 5 0 0
Neurological Symptoms:
Peripheral 79 0 0 0 0
Central 71 7 0 1 0
Figure 2 CT scan of the liver depicting metastases prior to therapy (A)
and the CR after 4 cycles of intravenous fotemustine in combination with
subcutaneous IL-2 and IFNa (B).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 840–845with respect to the neoplastic disease, (3) the induction cycle
consisted of three compared to two dosages of 100 mg m
72 fote-
mustine, and (4) the fotemustine was applied over a period of 4 h
compared to 1 h. Notably, in the here presented study all, but two
patients with metastatic ocular melanoma seen between December
1996 and October 2000 were considered for treatment according to
protocol; thus, a true consecutive series of walk-in patients, not
recruited from a screening programme were treated. Nevertheless,
the overall survival both for all patients, disregarding the applica-
tion route, and for those experiencing a beneﬁt from the
therapy, i.e. achieving an OR or SD, is very similar in either study
ranging around 1 year and 20 months, respectively. As discussed
above, a number of experimental and clinical observations suggest
a role of the immune system to restrain the progression of uveal
melanoma (Ksander and Chen, 1999). In this respect, the surgical
resection of only a fraction of the metastatic disease may be detri-
mental to the patients due to the stress induced immune
suppression (Rocha, 1985). The exact contribution of the immune
modulation to the therapeutic efﬁcacy of the presented treatment
protocol remains to be evaluated. Recent reports on the therapeutic
efﬁcacy of IL-2 in combination with histamine in hepatic metasta-
sis of uveal melanoma invigorate the hope that immune
modulation may serve as a new tool to treat this disease (Hell-
strand et al, 2000). Previous attempts to treat metastatic uveal
melanoma with chemotherapy relied on regimens established for
cutaneous melanoma (Woll et al, 1999; Shields, 1993). Despite
the fact that these two tumours are derived from the same cell
type, many genetic and phenotypic distinctions differentiate them
from each other. By means of an ex vivo ATP-based tumour
chemosensitivity Myatt et al (1997) were able to demonstrate that
alkylating agents were clearly superior to metabolic inhibitors such
as 5-ﬂuorouracil and spindle inhibitors such as vincristine. More-
over, cisplatin or MTIC, i.e. the active metabolite of dacarbazine
and temozolomide, showed only a moderate activity in this assay.
In their study, the best chemosensitivity of uveal melanoma was
observed for the combination of treosulfan and gemcitabine.
Unfortunately, fotemustine was not assessed in this study.
The overall 1 year survival rate with metastatic uveal melanoma
has been reported at 13%, with a median survival of only 5 months
(Woll et al, 1999; Kath et al, 1993; Shields et al, 1996; Pyrhonen,
1998). Subgroup analysis, however, shows a great diversity in over-
all survival, depending on the presence of different prognostic
parameters, such as metastatic sites or elevated LDH. Hence, the
clinical outcome of different treatment regimens for metastatic
disease is difﬁcult to evaluate if these prognostic parameters are
not taken into account (Eskelin et al, 1999). Moreover, only a
few clinical trials have assessed the impact of systemic therapy
and most of these reports were either based on retrospective analy-
sis or small numbers of patients. Thus, metastatic uveal melanoma
is still considered to be an incurable disease, with complete
responses being only anecdotal (Woll et al, 1999; Pyrhonen,
1998). To this end, the most data gained in prospectively designed
clinical trials are available for the nitrosurea fotemustine (Leyvraz et
al, 1997; Salmon et al, 1998; Terheyden et al, 1998, 2000; Jackel et
al, 2001).
Fotemustine alkylates the thiolate active sites of three intracellular
enzymes, i.e. thioredoxin reductase, glutathione reductase, and ribo-
nucleotide reductase, resulting in their inhibition. Moreover, it has
alkylating and carbamoylating effects on nucleic acids (Hayes et al,
1997). Both effects may induce the expression of stress molecules
such as hsp70 or MICA which can link chemo- and immunotherapy
(Weichenthal et al, 1998). To this end, fotemustine, in combination
with sequential immunotherapy for treatment of metastatic ocular
melanoma, resulted in a median survival of one year (95% conﬁ-
dence interval 347 and 390 days); the overall survival of patients
experiencing an objective beneﬁt of this therapy in the form of an
objective response or a stable disease was 19 months. This survival
is substantially better than that reported for other non-fotemustine
based treatment options (Woll et al, 1999; Pyrhonen, 1998). Since
the present study was not prospectively randomised into hepatic
arterial vs intravenous chemotherapy, the lack of a signiﬁcant survi-
val beneﬁt of the more invasive therapy can only be taken as a trend
advocating such a study.
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Figure 3 Overall survival according to best clinical response: OR (solid line), SD (dotted line) or PD (dashed line).
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